MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the first patient has been enrolled in the Phase 3 NODE-303 study. NODE-303 is the Company’s open-label, global safety study of etripamil, […]
Other News
Tenaya Therapeutics Closes $92 Million Series B Financing
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2019 /PRNewswire/ — Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease, today announced the successful completion of a $92 million Series B financing. The financing round was led by Casdin Capital and included […]
Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update
Arterial hypertension: preparing for the pivotal Phase III study of firibastat in patients with resistant arterial hypertension Heart failure: the first patients were enrolled in June in QUORUM, a Phase IIb study of firibastat in heart failure PARIS and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX […]
Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, today announced the appointment of physician and scientist Andrew Bellinger, M.D., Ph.D., as the company’s chief scientific officer. Dr. Bellinger joins Verve from […]
University Hospitals Completes First Evolut™ PRO+ Case in the World
UH Harrington Heart & Vascular Institute continues reputation as global leader in TAVR CLEVELAND — Physicians at University Hospitals Cleveland Medical Center completed the first procedure in the world using Medtronic’s new Evolut™ PRO+ TAVR System. Guilherme Attizzani, MD, Director, Valve and Structural Heart Disease Center, and Cristian Baeza, […]
Third-party evaluation confirms safety profile of Philips Stellarex .035″ low-dose drug-coated balloon
Primary safety analysis of Stellarex drug-coated balloon (DCB) three-year data, comprising the largest published, pooled set of randomized controlled trial (RCT) data for a single paclitaxel-based device, shows no difference in mortality between patients treated with the Philips Stellarex DCB and those treated with percutaneous angioplasty, the current standard of […]
Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution
LISLE, Ill, Oct. 1, 2019 /PRNewswire/ — Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The expansion syndicate for the LSP-led round includes new investment from an additional […]
ControlRad™ Secures $15 Million Series B Financing, Expands Board of Directors
Financing Round Led by Questa Capital to Fuel Commercialization of ControlRad Trace Mobile C-arm Radiation Reduction Technology Medical Device Industry Veterans Ryan Drant and Tim Patrick Join Board ATLANTA–(BUSINESS WIRE)–ControlRad, Inc., a privately held medical technology company focused on dramatically reducing unnecessary radiation exposure during fluoroscopically guided procedures (FGP), today […]
Angel Medical Systems Inc. Assembles World-Class Medical Advisory Board
EATONTOWN, N.J., Oct. 1, 2019 /PRNewswire/ — Angel Medical Systems Inc. is pleased to announce the creation of a Medical Advisory Board (MAB) coincident with the commercial release of the AngelMed Guardian® System, the world’s first implantable Acute Coronary Syndrome (ACS) event detector with real time patient notifications. Members of the MAB will […]
Zynex Announces 95% Order Growth
ENGLEWOOD, Colo., Oct. 2, 2019 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced 95% year over year order growth for the third quarter 2019. Orders in the third quarter of 2019 […]
Recent
Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders
CardioMech Shareholders Appoint Ramin Mousavi as Chairman of the Board
HOPPR Launches Presto, Unlocking AI Draft Reporting in Existing Radiology Workflows
Popular
- No commented posts yet